N Babu Rajendran1, N T Mutters2, G Marasca3, M Conti4, F Sifakis5, C Vuong6, A Voss7, J R Baño8, E Tacconelli9. 1. Division of Infectious Diseases, Department of Internal Medicine I, University Hospital Tübingen, Tübingen, Germany. Electronic address: Nithya.Babu-Rajendran@med.uni-tuebingen.de. 2. Institute for Infection Prevention and Hospital Epidemiology, University Medical Centre Freiburg, Freiburg, Germany. 3. Department of Infectious Disease, IRCCS Ospedale Classificato Equiparato Sacro Cuore, Verona, Italy. 4. Division of Infectious Diseases, Department of Diagnostic and Public Health, University of Verona, Verona, Italy. 5. Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA. 6. AiCuris Anti-infective Cures GmbH, Wuppertal, Germany. 7. Department of Medical Microbiology, Radboud University Medical Centre, Nijmegen, the Netherlands. 8. Infectious Diseases, Microbiology and Preventive Medicine, Hospital Universitario Virgen Macarena, Department of Medicine, University of Sevilla, Biomedicine Institute of Sevilla (IBiS), Sevilla, Spain. 9. Division of Infectious Diseases, Department of Internal Medicine I, University Hospital Tübingen, Tübingen, Germany; Division of Infectious Diseases, Department of Diagnostic and Public Health, University of Verona, Verona, Italy.
Abstract
OBJECTIVES: In 2017 the WHO published a global priority list of 12 antibiotic-resistant bacteria (ARB) in urgent need of new antibiotics. We aimed to identify and assess publicly accessible mandatory surveillance systems and outbreaks reporting for these pathogens in the 28 European Union and four European Free Trade Association member states. METHODS: Compulsory reporting was mapped by reviewing national documents without applying language restrictions and through expert consultation. Information on surveillance targets, indicators, metrics and dissemination modalities was extracted and a qualitative assessment was performed for open access systems only. RESULTS: Twenty-one countries (66%) had a mandate to survey at least one among the 12 WHO priority pathogens; 15 provided access to surveillance frameworks. These systems covered most frequently carbapenem-resistant Enterobacteriales (12; 38%), methicillin-resistant Staphylococcus aureus (12; 38%), and vancomycin-resistant enterococci (8; 25%). None of the European countries required reporting of resistance in Salmonella, Campylobacter, Helicobacter pylori and Neisseria gonorrhoeae. High heterogeneity was observed in data collection, reporting and dissemination among countries with clinical outcomes and risk factors being reported in less than half (22% and 25%). Only six countries (19%) implemented mandatory surveillance of outbreaks due to at least one WHO priority pathogen. CONCLUSIONS: Our review shows that despite the increasing burden of ARB on the European population, very few countries implemented mandatory surveillance and outbreak reporting of the WHO priority pathogens. International efforts are needed to define the effectiveness of implementing mandatory reporting of these pathogens and to assess their role in reducing the spread of ARB in health-care and community settings.
OBJECTIVES: In 2017 the WHO published a global priority list of 12 antibiotic-resistant bacteria (ARB) in urgent need of new antibiotics. We aimed to identify and assess publicly accessible mandatory surveillance systems and outbreaks reporting for these pathogens in the 28 European Union and four European Free Trade Association member states. METHODS: Compulsory reporting was mapped by reviewing national documents without applying language restrictions and through expert consultation. Information on surveillance targets, indicators, metrics and dissemination modalities was extracted and a qualitative assessment was performed for open access systems only. RESULTS: Twenty-one countries (66%) had a mandate to survey at least one among the 12 WHO priority pathogens; 15 provided access to surveillance frameworks. These systems covered most frequently carbapenem-resistant Enterobacteriales (12; 38%), methicillin-resistant Staphylococcus aureus (12; 38%), and vancomycin-resistant enterococci (8; 25%). None of the European countries required reporting of resistance in Salmonella, Campylobacter, Helicobacter pylori and Neisseria gonorrhoeae. High heterogeneity was observed in data collection, reporting and dissemination among countries with clinical outcomes and risk factors being reported in less than half (22% and 25%). Only six countries (19%) implemented mandatory surveillance of outbreaks due to at least one WHO priority pathogen. CONCLUSIONS: Our review shows that despite the increasing burden of ARB on the European population, very few countries implemented mandatory surveillance and outbreak reporting of the WHO priority pathogens. International efforts are needed to define the effectiveness of implementing mandatory reporting of these pathogens and to assess their role in reducing the spread of ARB in health-care and community settings.
Authors: Margo VanOeffelen; Marcus Nguyen; Derya Aytan-Aktug; Thomas Brettin; Emily M Dietrich; Ronald W Kenyon; Dustin Machi; Chunhong Mao; Robert Olson; Gordon D Pusch; Maulik Shukla; Rick Stevens; Veronika Vonstein; Andrew S Warren; Alice R Wattam; Hyunseung Yoo; James J Davis Journal: Brief Bioinform Date: 2021-11-05 Impact factor: 13.994
Authors: Gamal Wareth; Christian Brandt; Lisa D Sprague; Heinrich Neubauer; Mathias W Pletz Journal: BMC Microbiol Date: 2021-07-10 Impact factor: 3.605